HIGH REMISSION RATE WITH HIGH DOSE MELPHALAN AND ETOPOSIDE (VP-16) AND AUTOLOGOUS STEM CELL SUPPORT IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
High dose chemotherapy with autologous stem cell support has been shown to improve survival and quality of life in MM patients (pts). The achievement of post transplant complete remission (CR) seems to be a major prognostic factor in this setting. Nevertheless, the optimal high dose combination has not been yet defined. Melphalan is widely used and VP-16 is effective as a single agent in MM. We conducted a phase II clinical trial with melphalan and VP-16 in MM patients to evaluate the impact of an intensified preparatory regimen on the CR rate. 46 pts, age 37-64 (median 49), with newly diagnosed MM stage II (5) and III (41) were treated between 1/95 and 9/98. Pts were enrolled at best response to first line chemotherapy. The high dose chemotherapy regimen was melphalan 60mg/M 2 /D × 3 days, and undiluted VP 16 600mg/M 2 given over 4 hours × 3 days. The median time to engraftment was 10 days (7-13). Treatment-related complications Ͼgrade II included respiratory failure 1 pt and mucositis 35 pts. There was no treatmentrelated mortality. 25 out of the 40 patients (56%) achieved complete remission 3 months post transplant. 35 pts (76%) are progression-free (pf), and 11 patients (22%) progressed at a median follow up of 24 mo. Two patients died. 13 patients are Ͼ30 mo from transplant (median 36 mo): 4 patients in this group were in PR post transplant, all of which relapsed, and of the 9 patients who achieved CR, only 2 progressed and 7 are in remission.Conclusion: Post-transplant remission is a major prognostic factor for predicting prolonged PF. The combination of high dose melphalan and VP 16 is feasible, safe and induces high CR rate. S135
